

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**GURPARTAP S. BASRAI, doing business
as MEDICAL PAVILION PHARMACY
9460 No Name Uno, Ste. 100
Gilroy, CA 95020**

Original Permit License No. PHY 47105,

and

**DAVID DONG KIEU
1476 Myrtle Ave.
San Jose, CA 95118**

Pharmacist License No. RPH 61202

Respondents.

Case No. 5738

OAH No. 2016091006

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER FOR PUBLIC
REPROVAL AS TO GURPARTAP S.
BASRAI, doing business as MEDICAL
PAVILION PHARMACY**

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Repeval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on March 20, 2017.

It is so ORDERED on February 17, 2017.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

Amy Gutierrez, Pharm.D.
Board President

1 KATHLEEN A. KENEALY
Acting Attorney General of California
2 DIANN SOKOLOFF
Supervising Deputy Attorney General
CARTER OTT
3 Deputy Attorney General
State Bar No. 221660
4 1515 Clay Street, 20th Floor
P.O. Box 70550
5 Oakland, CA 94612-0550
Telephone: (510) 879-0770
6 Facsimile: (510) 622-2270
E-mail: Carter.Ott@doj.ca.gov
7 *Attorneys for Complainant*

8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:
12 **GURPARTAP S. BASRAI, doing business**
as **MEDICAL PAVILION PHARMACY**
13 **9460 No Name Uno, Ste. 100**
Gilroy, CA 95020
14 **Original Permit License No. PHY 47105,**
15 **and**
16 **DAVID DONG KIEU**
17 **1476 Myrtle Ave.,**
San Jose, CA 95118
18 **Pharmacist License No. RPH 61202**
19
20 Respondents.

Case No. 5738
OAH No. 2016091006
STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER FOR PUBLIC
REPROVAL AS TO GURPARTAP S.
BASRAI, doing business as MEDICAL
PAVILION PHARMACY
[Bus. & Prof. Code § 495]

21 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
22 entitled proceedings that the following matters are true:

23 PARTIES

24 1. Virginia Herold ("Complainant") is the Executive Officer of the Board of Pharmacy
25 ("Board"). She brought this action solely in her official capacity and is represented in this matter
26 by Kathleen A. Kenealy, Acting Attorney General of the State of California, by Carter Ott,
27 Deputy Attorney General.
28

1 2. Respondent Gurpartap S. Basrai, doing business as Medical Pavilion Pharmacy
2 (“Respondent”) is representing himself in this proceeding and has chosen not to exercise his right
3 to be represented by counsel.

4 JURISDICTION

5 3. On or about July 27, 2005, the Board of Pharmacy issued Original Permit License
6 Number PHY 47105 to Respondent. The Original Permit License was in full force and effect at
7 all times relevant to the charges brought in Accusation No. 5738 and will expire on July 1, 2017,
8 unless renewed.

9 4. Accusation No. 5738 was filed before the Board of Pharmacy (“Board”), Department
10 of Consumer Affairs and is currently pending against Respondent. The Accusation and all other
11 statutorily required documents were properly served on Respondent on July 20, 2016.
12 Respondent timely filed his Notice of Defense contesting the Accusation. A copy of Accusation
13 No. 5738 is attached as Exhibit A and incorporated herein by reference.

14 ADVISEMENT AND WAIVERS

15 5. Respondent has carefully read, and understands the charges and allegations in
16 Accusation No. 5738. Respondent has also carefully read, and understands the effects of this
17 Stipulated Settlement and Disciplinary Order for Public Repeoval.

18 6. Respondent is fully aware of his legal rights in this matter, including the right to a
19 hearing on the charges and allegations in the Accusation; the right to be represented by counsel at
20 his own expense; the right to confront and cross-examine the witnesses against him; the right to
21 present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel
22 the attendance of witnesses and the production of documents; the right to reconsideration and
23 court review of an adverse decision; and all other rights accorded by the California
24 Administrative Procedure Act and other applicable laws.

25 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
26 every right set forth above.

27 ////

28 ////

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CULPABILITY

8. Respondent admits the truth of each and every charge and allegation in Accusation No. 5738.

9. Respondent agrees that his Original Permit License is subject to discipline and he agrees to be bound by the Disciplinary Order below.

CONTINGENCY

10. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent. By signing the stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Repeval shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

11. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order for Public Repeval, including Portable Document Format (PDF) and facsimile signatures thereto, shall have the same force and effect as the originals.

12. This Stipulated Settlement and Disciplinary Order for Public Repeval is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order for Public Repeval may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

1 13. In consideration of the foregoing admissions and stipulations, the parties agree that
2 the Board may, without further notice or formal proceeding, issue and enter the following
3 Disciplinary Order:

4 **DISCIPLINARY ORDER**


5 IT IS HEREBY ORDERED that Original Permit License No. PHY 47105 issued to
6 Respondent Gurpartap S. Basrai, doing business as Medical Pavilion Pharmacy shall be publicly
7 reprovod by the Board of Pharmacy under Business and Professions Code section 495 in
8 resolution of Accusation No. 5738, attached as Exhibit A.

9 Cost Recovery. Within 90 days of the effective date of this Order, Respondent shall pay
10 \$5,018 to the Board for its costs associated with the investigation and enforcement of this matter.
11 If Respondent fails to pay the Board costs as ordered, Respondent shall not be allowed to renew
12 their Original Permit License until Respondent pays costs in full.

13 **ACCEPTANCE**

14 I have carefully read the Stipulated Settlement and Disciplinary Order for Public Reprval.
15 I understand the stipulation and the effect it will have on my Original Permit License. I enter into
16 this Stipulated Settlement and Disciplinary Order for Public Reprval voluntarily, knowingly, and
17 intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

18
19 DATED: 01/09/2017



20 _____
21 GURPARTAP S. BASRAI, doing business as
22 MEDICAL PAVILION PHARMACY
23 Respondent
24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

Dated: 1/10/17

Respectfully submitted,

KATHLEEN A. KENEALY
Acting Attorney General of California
DIANN SOKOLOFF
Supervising Deputy Attorney General



CARTER OTT
Deputy Attorney General
Attorneys for Complainant

SF2016900135

Exhibit A

Accusation No. 5738

1 KAMALA D. HARRIS
Attorney General of California
2 DIANN SOKOLOFF
Supervising Deputy Attorney General
3 CARTER OTT
Deputy Attorney General
4 State Bar No. 221660
1515 Clay Street, 20th Floor
5 P.O. Box 70550
Oakland, CA 94612-0550
6 Telephone: (510) 622-2219
Facsimile: (510) 622-2270
7 E-mail: Carter.Ott@doj.ca.gov
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:
12
13 **GURPARTAP S. BASRAI, doing business**
as MEDICAL PAVILION PHARMACY
14 **9460 No Name Uno, Ste. 100**
Gilroy, CA 95020
15 **Original Permit License No. PHY 47105,**
16 **and**
17 **DAVID DONG KIEU**
18 **1476 Myrtle Ave.,**
San Jose, CA 95118
19 **Pharmacist License No. RPH 61202**
20 Respondents.

Case No. 5738

ACCUSATION

21
22 Complainant alleges:

23 PARTIES

- 24 1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity
25 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.
26 2. On or about July 27, 2005, the Board of Pharmacy issued Original Permit License
27 Number PHY 47105 to Gurpartap S. Basrai to do business as Medical Pavilion Pharmacy
28 ("Pharmacy MP Pharmacy"). The Original Permit License was in full force and effect at all

1 times relevant to the charges brought in this Accusation and will expire on July 1, 2016, unless
2 renewed.

3 3. On or about July 24, 2008, the Board of Pharmacy issued Pharmacist License
4 Number RPH 61202 to David Dong Kieu ("Respondent Kieu"). The Pharmacist License was in
5 full force and effect at all times relevant to the charges brought in this Accusation and will expire
6 on August 31, 2017, unless renewed. Since June 1, 2010, Respondent Kieu served as Respondent
7 MP Pharmacy's Pharmacist-in-Charge ("PIC").

8 JURISDICTION

9 4. This Accusation is brought before the Board of Pharmacy ("Board"), Department of
10 Consumer Affairs, under the authority of the following laws. All section references are to the
11 Business and Professions Code unless otherwise indicated.

12 5. Section 118, subdivision (b) states:

13 "(b) The suspension, expiration, or forfeiture by operation of law of a license issued by a
14 board in the department, or its suspension, forfeiture, or cancellation by order of the board or by
15 order of a court of law, or its surrender without the written consent of the board, shall not, during
16 any period in which it may be renewed, restored, reissued, or reinstated, deprive the board of its
17 authority to institute or continue a disciplinary proceeding against the licensee upon any ground
18 provided by law or to enter an order suspending or revoking the license or otherwise taking
19 disciplinary action against the licensee on any such ground."

20 6. Section 4300 of states, in part:

21 "(a) Every license issued may be suspended or revoked.

22 "(b) The board shall discipline the holder of any license issued by the board, whose default
23 has been entered or whose case has been heard by the board and found guilty, by any of the
24 following methods:

25 "(1) Suspending judgment.

26 "(2) Placing him or her upon probation.

27 "(3) Suspending his or her right to practice for a period not exceeding one year.

28 "(4) Revoking his or her license.

1 “(5) Taking any other action in relation to disciplining him or her as the board in its
2 discretion may deem proper.

3 ...

4 “(e) The proceedings under this article shall be conducted in accordance with Chapter 5
5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board
6 shall have all the powers granted therein. The action shall be final, except that the propriety of
7 the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of
8 Civil Procedure.”

9 RELEVANT STATUTES AND REGULATIONS

10 7. Health and Safety Code section 111335 states:

11 “Any drug or device is misbranded if its labeling or packaging does not conform to the
12 requirements of Chapter 4 (commencing with Section 110290).”

13 8. Health and Safety Code section 111375 states, in part:

14 “Any drug or device is misbranded unless its labeling bears all of the following
15 information:

16 ...

17 “(c) Adequate warning against unsafe dosage or methods or duration of administration or
18 application.

19 “Warnings shall be in a manner and form as are necessary for the protection of users.

20 “If the department determines that any requirement of subdivision (a), as applied to any
21 drug or device, is not necessary for the protection of the public health, the department may adopt
22 regulations exempting the drug or device from these requirements.

23 Any drug or device exempted under Section 502(f) of the federal act (21 U.S.C. Sec. 352(f)) is
24 exempt from the requirement of this section. The department, however, may adopt any regulation
25 including a drug or device within, or excluding a drug or device from the requirements of this
26 section, whether or not the inclusion or exclusion of the drug or device is in accord with the
27 federal act.”

28 /////

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

9. Health and Safety Code section 111400 states:

“Any drug or device is misbranded if it is dangerous to health when used in the dosage, or with the frequency or duration prescribed, recommended, or suggested in its labeling.”

10. Section 4169 states, in part:

“(a) A person or entity shall not do any of the following:

...

“(3) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably should have known were misbranded, as defined in Section 111335 of the Health and Safety Code.

....”

11. Section 4301 states, in part:

“The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.

Unprofessional conduct shall include, but is not limited to, any of the following:

...

“(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.

....”

12. Section 4306.5 states, in part:

“Unprofessional conduct for a pharmacist may include any of the following:

...

“(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the provision of services.

....”

1 COST RECOVERY

2 13. Section 125.3 provides, in part, that the Board may request the administrative law
3 judge to direct a licentiate found to have committed a violation or violations of the licensing act
4 to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

5 RELEVANT DRUG INFORMATION

6 14. "Domperidone," also known as Motilium, is an anti-dopaminergic drug which acts as
7 an antiemetic and a prokinetic agent. It is used in many countries for the treatment of
8 gastroparesis, a condition in which the stomach cannot empty itself of food in a normal fashion.
9 Compounding with domperidone is not allowed in the United States with the exception of
10 investigational new drug application filing. Only Dougherty's Pharmacy, located in Dallas,
11 Texas, is approved to compound domperidone at this time. Distribution of any domperidone-
12 containing products is illegal. The Federal Drug Administration ("FDA") has instructed its field
13 personnel to detain shipments of domperidone and refuse its admission into the United States.

14 15. Domperidone is believed to promote lactation. But the drug is not approved in any
15 country, including the United States, for promoting lactation. In fact, the FDA warns against
16 using domperidone for promoting lactation. In particular, on June 7, 2004, the FDA published a
17 talk paper titled "FDA Warns Against Women Using Unapproved Drug, Domperidone, to
18 Increase Milk Production,"¹ in which it warns about the public risks associated with use of the
19 drug:

20 The [FDA] is concerned with the potential public health risks associated with
21 domperidone. There have been several published reports and case studies of
22 cardiac arrhythmias, cardiac arrest, and sudden death in patients receiving an
23 intravenous form of domperidone In several countries where the oral form
24 of domperidone continues to be marketed, labels for the product contain specific
25 warnings against use of domperidone by breastfeeding women and note that the
26 drug is excreted in breast milk that could expose a breastfeeding infant to
27 unknown risks. Because of the possibility of serious adverse effects, FDA
28 recommends that breastfeeding women not use domperidone to increase milk
production.

...

1 <http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886.htm>

1 The letters issued by FDA today stated that all drug products containing
2 domperidone (whether compounded or not) violate the Federal Food, Drug, and
3 Cosmetic Act (the Act) because they are unapproved new drugs and misbranded.
4 In addition, distribution within the U.S., or importation of domperidone-
5 containing products, violates the law. FDA informed the warning letter recipients
6 that further violations of the Act may result in enforcement actions including
7 seizure and injunction.

8 16. On April 14, 2015, the Board issued a "subscriber alert" stating: "Domperidone is
9 **not** FDA-approved for any use in humans in the United States. Drug products compounded using
10 domperidone are subject to the approval requirements of the Federal Food, Drug, and Cosmetic
11 Act."

12 17. The FDA currently permits patients of 12 years of age and older with various
13 gastrointestinal conditions that are refractory to standard therapy to be treated with Domperidone
14 through an Expanded Access Program. Physicians interested in obtaining expanded access to
15 Domperidone must submit an investigational new drug application to the FDA. Currently, no
16 pharmacies are authorized to compound Domperidone under the FDA's Expanded Access
17 Program.

18 FACTUAL BACKGROUND

19 18. In August 2015, in response to an inquiry from a Board investigator, Respondent MP
20 Pharmacy provided records showing that it had dispensed Domperidone as follows:

- 21 a. 3,000 capsules of Domperidone 10 mg, between April 23, 2015 and August 11,
22 2015;
- 23 b. 240 capsules of Domperidone 20 mg, between May 7, 2015 and 16, 2015;
- 24 c. 90 capsules of Domperidone 8 mg on June 12, 2015; and
- 25 d. 300 capsules of Domperidone 5 mg on May 29, 2015.

26 //

27 //

28 //

//

//

1 19. In response to the same Board inquiry, in August 2015, Respondent Kieu, on behalf
2 of Respondent MP Pharmacy, provided the following statement:

3 "A. Domperidone is not an FDA approved drug.

4 ...

5 "E. From 4/15/15 to 8/25/15, 3630 capsules and 37.02 grams of domperidone were
6 compounded and 3150 capsule (sic) and 32.52 grams of domperidone were dispensed [by
7 Respondent MP Pharmacy]. None of the prescriptions were dispensed to breastfeeding mothers
8 to increase lactation. They were all used for GI motility disorders.

9"

10 FIRST CAUSE FOR DISCIPLINE

(Sale of Misbranded Drug)

11 (Bus. & Prof. Code § 4169, subd. (a)(3); and Health and Safety Code §§ 111335;
12 111375, subd. (c); and 111400)

13 20. Respondent MP Pharmacy and Respondent Kieu have subjected their Original Permit
14 and Pharmacist Licenses, respectively, to disciplinary action for their trade, sale, or transfer of a
15 dangerous drug that they knew or reasonably should have known was misbranded, as defined in
16 Health and Safety Code section 111335. (Bus. & Prof. Code § 4169, subd. (a)(3); and Health and
17 Safety Code §§ 111335; 111375, subd. (c); and 111400). The circumstances are set forth in
18 paragraphs 14 through 19, above.

19 SECOND CAUSE FOR DISCIPLINE

(Failure to Exercise Professional Judgment)

20 (Bus. & Prof. Code § 4306.5, subd. (b))

21 21. Respondent MP Pharmacy and Respondent Kieu have subjected their Original Permit
22 and Pharmacist Licenses, respectively, to disciplinary action for failing to exercise or implement
23 their best professional judgment or corresponding responsibility with regard to the dispensing or
24 furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the
25 provision of services. (Bus. & Prof. Code § 4306.5, subd. (b)). The circumstances are set forth in
26 paragraphs 14 through 19, above.

27 /////

28 /////

//////

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

THIRD CAUSE FOR DISCIPLINE

(Unprofessional Conduct – Violation of the Law Governing Pharmacy)
(Bus. & Prof. Code § 4301, subd. (o); and Health and Safety Code §§ 111375, sub. (c),
and 111400)

22. Respondent MP Pharmacy and Respondent Kieu have subjected their Original Permit and Pharmacist Licenses, respectively, to disciplinary action for unprofessional conduct by violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate applicable federal and state laws and regulations governing pharmacy. ((Bus. & Prof. Code § 4301, subd. (o); and Health and Safety Code § 111375, sub. (c), and 111400)). The circumstances are set forth in paragraphs 14 through 21, above.

DISCIPLINARY CONSIDERATIONS

23. To determine the degree of discipline, if any, to be imposed on Respondent MP Pharmacy, Complainant alleges that on or about October 5, 2011, in a prior action, the Board issued Citation Number CI 2009 42612 against Respondent MP Pharmacy for Dispensing Dangerous Drug in Incorrectly Labeled Container/Prescription Container – Requirements for Labeling/Protocol; Expiration Date; Physical Description (Bus. & Prof. Code § 4077, subd. (a) and 4076, subds. (a)(1), (a)(9), and (a)(11)(A)). The Citation is now final and incorporated by reference as if fully set forth.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters alleged in this Accusation, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Original Permit License Number PHY 47105, issued to Respondent MP Pharmacy;

2. Revoking or suspending Pharmacist License Number RPH 61202, issued to Respondent Kieu;


/////
/////
/////
/////

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

3. Ordering Respondent MP Pharmacy and Respondent Kieu to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and

4. Taking such other and further action as deemed necessary and proper.

DATED: 7/11/16



VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

SF2016900135